On April 30, 2026, Reuters reported that Bristol-Myers Squibb Company (NYSE:BMY) announced first-quarter adjusted earnings of $1.58 per share, which came in above analysts\u2019 average estimate of $1.42. The revenue of $11.49 billion also exceeded expectations of $10.9 billion. Shares rose by 4%.<\/p>\n
Eliquis produced $4.14 billion in quarterly sales with growth of 16% YoY. Chief Commercialization Officer Adam Lenkowsky said that demand continues to be solid, with new prescription share over 75%, adding that the drug\u2019s performance should support growth later this year. Bristol-Myers Squibb Company (NYSE:BMY)\u2019s growth portfolio, which includes cell therapy Breyanzi and Camzyos, went up by 12% to $6.23 billion. This made up more than half of the total revenue.<\/p>\n
![\"Bristol-Myers](\"https:\/\/www.europesays.com\/uk\/wp-content\/uploads\/2026\/05\/68a1d418129d70396778f0a3e8523633.jpeg\")
Bristol-Myers Squibb Company (BMY) Myers Beats Quarterly Profit Estimates <\/p>\n
Opdivo sales declined 5% to $2.15 billion and missed projections of $2.33 billion. CFO David Elkins said that the shortfall is because of wholesaler inventory cutbacks, and the company is still watching whether levels return to normal.<\/p>\n
Trung Huynh, an analyst at RBC Capital Markets, believes second-half catalysts, such as the probable approval of a next-generation cancer therapy and late-stage milvexian data, are more important than current quarterly results.<\/p>\n
The company reiterated its sales outlook for 2026 of $46.0 billion to $47.5 billion, trending toward the higher end.<\/p>\n
Bristol-Myers Squibb Company (NYSE:BMY) is involved in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. It provides small molecules, biologics, and CAR-T cell treatments.<\/p>\n
While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the\u00a0best short-term AI stock<\/strong><\/a>.<\/p>\n READ NEXT:\u00a0<\/strong>33 Stocks That Should Double in 3 Years<\/strong><\/a> and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy<\/a><\/strong>.<\/strong>\u00a0<\/strong><\/p>\n